Microencapsulation for Enhanced Bioavailability of Fish Oil - Acute Study

Not Applicable

Recruiting

• Conditions: Bioavailabilty of microencapsulated omega-3 oil as a dietary supplement; Diet and Nutrition - Other diet and nutrition disorders

• Registration Number: ACTRN12611000012976
• Lead Sponsor: CSIRO Preventative Health Flagship

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-01-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Male and Females aged between 18-70 years
2. Normal dietary habits (no medically prescribed diet, no slimming diet, and no vegan or macrobiotic diet).
3. Body Mass Index >18 kg/m2 < 35kg/m2
4. Apparently healthy: no reported current or previous metabolic diseases, gastrointestinal disorders, renal or cardiovascular disease.
5. Person having given their specific consent in writing.

Exclusion Criteria

1. Regular use of supplements containing omega-3 essential fatty acids must have ceased 2 months prior to the start of the study.
2. Regular consumption of foods supplemented with omega-3 essential fatty acids such as some breads and milk products
3. Consumption of fish as part of regular dietary patterns
4. Current relevant medical treatment (subject to judgement of the investigator).
5. High alcohol consumption (>21 standard drinks/week)
6. Reported participation in another biomedical trial 3 months before the start of the study or during the study.
7. Food allergies or intolerances (dairy, lactose, peanuts, shellfish, etc…).
8. Recent history (within 12 months) of substance abuse including alcohol abuse.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Plasma total fatty acids at each appropriate time point.[As a crossover design this study will focus on acute response of ingestion of the 3 test products as measured in plasma free fatty acids. Baseline measurements will be taken at timepoint 0, then at 2, 4, 6, 24 and 48 hours post ingestion for each treatment. Each treatment is given on one occasion with 6 weeks between treatments.]

Secondary Outcome Measures

Name	Time	Method
Acute response study: Red blood cell membrane fatty acids at t=0 weeks to monitor accumulation of membrane DHA/EPA over the 3 treatments.[Acute response study: as a crossover design this study will focus on acute response of ingestion of the 3 test products. secondary outcomes listed above.]